Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functional Nf1 to apoptosis in the absence of protein kinase C
- PMID: 27741517
- PMCID: PMC5356664
- DOI: 10.18632/oncotarget.12607
Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functional Nf1 to apoptosis in the absence of protein kinase C
Abstract
Nf1 mutations or deletions are suggested to underlie the tumor predisposition of NF1 (neurofibromatosis type 1) and few treatments are available for treating NF1 patients with advanced malignant tumors. Aberrant activation of Ras in Nf1-deficient conditions is responsible for the promotion of tumorigenesis in NF1. PKC is proven to be an important factor in supporting the viability of Nf1-defected cells, but the molecular mechanisms are not fully understood. In this study, we demonstrate that the inhibition of protein kinase C (PKC) by 1-O-Hexadecyl-2-O-methyl-rac-glycerol (HMG, a PKC inhibitor) preferentially sensitizes Nf1-defected cells to apoptosis, via triggering a persistent mitotic arrest. In this process, Ral A is activated. Subsequently, Chk1 is phosphorylated and translocated to the nucleus. Silencing Ral A significantly blocks Chk1 nuclear translocation and releases HMG-treated Nf1-deficient cells from mitotic arrest, resulting in the reduction of the magnitude of apoptosis. Thus, our study reveals that PKC is able to maintain the homeostasis or viability of Nf1-defected cells and may serve as a potential target for developing new therapeutic strategies.
Keywords: Chk1; Nf1; Ral A; apoptosis; mitotic catastrophe.
Conflict of interest statement
No potential conflicts of interest were disclosed.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356664/bin/oncotarget-07-84326-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356664/bin/oncotarget-07-84326-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356664/bin/oncotarget-07-84326-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356664/bin/oncotarget-07-84326-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356664/bin/oncotarget-07-84326-g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356664/bin/oncotarget-07-84326-g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356664/bin/oncotarget-07-84326-g007.gif)
Similar articles
-
Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells.Cell Cycle. 2014;13(15):2340-8. doi: 10.4161/cc.29297. Cell Cycle. 2014. PMID: 25483185 Free PMC article.
-
Ral overactivation in malignant peripheral nerve sheath tumors.Mol Cell Biol. 2009 Jul;29(14):3964-74. doi: 10.1128/MCB.01153-08. Epub 2009 May 4. Mol Cell Biol. 2009. PMID: 19414599 Free PMC article.
-
The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.Clin Cancer Res. 2006 Sep 15;12(18):5533-42. doi: 10.1158/1078-0432.CCR-06-0792. Clin Cancer Res. 2006. PMID: 17000690
-
Neurofibromatosis 1: closing the GAP between mice and men.Curr Opin Genet Dev. 2003 Feb;13(1):20-7. doi: 10.1016/s0959-437x(02)00015-1. Curr Opin Genet Dev. 2003. PMID: 12573431 Review.
-
Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors.Front Biosci (Landmark Ed). 2011 Jan 1;16(3):937-51. doi: 10.2741/3727. Front Biosci (Landmark Ed). 2011. PMID: 21196210 Review.
Cited by
-
The RAL Enigma: Distinct Roles of RALA and RALB in Cancer.Cells. 2022 May 14;11(10):1645. doi: 10.3390/cells11101645. Cells. 2022. PMID: 35626682 Free PMC article. Review.
-
Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling.CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):350-361. doi: 10.1002/psp4.12603. Epub 2021 Apr 8. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33792207 Free PMC article.
-
Chronic low dose arsenic exposure preferentially perturbs mitotic phase of the cell cycle.Genes Cancer. 2019 Feb;10(1-2):39-51. doi: 10.18632/genesandcancer.185. Genes Cancer. 2019. PMID: 30899418 Free PMC article.
-
The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG.Cell Death Dis. 2018 Feb 7;9(2):165. doi: 10.1038/s41419-017-0247-5. Cell Death Dis. 2018. PMID: 29416003 Free PMC article.
-
Ral signaling pathway in health and cancer.Cancer Med. 2017 Dec;6(12):2998-3013. doi: 10.1002/cam4.1105. Epub 2017 Oct 18. Cancer Med. 2017. PMID: 29047224 Free PMC article. Review.
References
-
- Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. Loss of NF1 resultes in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12:144–148. - PubMed
-
- Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104:593–604. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous